A practical guide for providers on helping patients locate Reyvow during the discontinuation period, plus transition strategies and workflow tips.
With Eli Lilly's permanent discontinuation of Reyvow (Lasmiditan), your practice is likely fielding more calls from patients unable to fill their prescriptions. As remaining supply dwindles toward the May 31, 2026 distribution end date, these calls will only increase.
This guide provides actionable strategies to help your patients find remaining Reyvow stock, manage the transition to alternatives, and reduce the operational burden on your practice.
As of early 2026, Reyvow's availability is uneven across the U.S.:
Understanding the barriers helps your staff respond effectively:
Run a report in your EHR to identify all patients with active Reyvow prescriptions. Don't wait for them to call — reach out first:
Proactive outreach reduces reactive phone calls and allows you to manage transitions on your schedule, not the pharmacy's.
Medfinder for Providers offers real-time pharmacy inventory information that can streamline the process of finding Reyvow for patients who still need it:
Train your front desk and nursing staff to use Medfinder when patients call about Reyvow availability. This empowers your team to provide immediate, actionable information.
When a patient's usual pharmacy is out of stock, help them transfer to a pharmacy that has it:
Encourage patients to fill their Reyvow prescriptions as soon as their insurance allows rather than waiting until they run out. Most plans permit refills when 75–80% of the previous supply has been used.
For patients with remaining refills, filling now rather than later significantly improves their chances of receiving the medication before supply is exhausted.
When transitioning patients to gepants or other alternatives that require prior authorization:
When transitioning patients, match the alternative to the clinical reason Reyvow was prescribed:
These patients were likely on Reyvow because it doesn't cause vasoconstriction. Transition to gepants:
If a patient was on Reyvow due to triptan non-response or preference, consider re-evaluating triptans:
For a patient-facing version of this information, direct patients to our alternatives to Reyvow guide.
Develop a brief SOP for your staff to handle Reyvow-related calls:
Rather than handling transitions one-off as patients call, consider:
Point patients to these resources for additional information:
The Reyvow discontinuation is an operational challenge, but it's manageable with proactive planning. Identify your affected patients now, standardize your transition workflow, and use tools like Medfinder to efficiently locate remaining supply.
The providers who plan ahead will turn a disruptive event into a smooth transition — and strengthen patient trust in the process.
For the clinical overview of the discontinuation, see our companion article: Reyvow shortage — what providers need to know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
